Sponsor pipeline

Yana Najjar clinical trial pipeline

Get alerts when Yana Najjar's trials change

5 active trials 3 recruiting 1 disease areas 4 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-08-21
Primary completion pushed: 2024-05-17 → 2026-10-07
Primary endpoint(s) modified
Enrollment closed, study ongoing
Completion pushed: 2027-05-31 → 2027-08-05
NCT04572451 Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in… · Phase 1

Active trials by phase

Early Phase 1
1
Phase 1
2
Not charted: 2 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials

NCT IDTitleConditionStatusUpdated
Phase 1
NCT04572451 Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in… Melanoma Active, Not Recruiting 2026-08-20
NCT03311308 A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma Advanced Melanoma Active, Not Recruiting 2026-06-30
Early Phase 1
NCT06216938 RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis Melanoma Recruiting 2026-04-13
Not specified
NCT04658303 Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma Melanoma Recruiting 2026-06-11
NCT06831071 Evaluation of Hypoxia in Primary Melanoma Melanoma Recruiting 2026-06-10

Disease areas by active trials

Melanoma (5)

Get alerts when Yana Najjar's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free